Big news today for #acromegaly patients and the rare disease community!
We are excited to announce the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for the first oral, once-daily, selectively-targeted somatostatin receptor type 2 agonist in development for the treatment of acromegaly. This marks the first NDA submission for Crinetics as a company, and we are grateful to all who made this milestone possible! We are now one step further along in our mission to transform the lives of people living with a wide range of endocrine-related diseases. Learn more: https://bit.ly/3XIQ5Sb